Stage II Esophageal Cancer Completed Phase 1 Trials for Erlotinib (DB00530)

IndicationStatusPhase
DBCOND0029703 (Stage II Esophageal Cancer)Completed1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT01561014Oxaliplatin, Fluorouracil, Erlotinib Hydrochloride, and Radiation Therapy Before Surgery and Erlotinib Hydrochloride After Surgery in Treating Patients With Locally Advanced Cancer of the Esophagus or Gastroesophageal JunctionTreatment
NCT00030498Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney DysfunctionTreatment